April 28, 2016

WASHINGTON, D.C. - April 28, 2016 - COPD Foundation and Evidera won the Best Personalized Medicine Advance or Application Award at the first annual Clinical & Research Excellence Awards. The Clinical and Research Excellence Awards – or CARE Awards – honor those who work in clinical research and development to make human lives better with new medicines. Run by Informa’s Pharma Intelligence, they are celebration of the brilliant minds, strategic thinkers, and risk takers who bring the hope of good health to humankind.

The Best Personalized Medicine Advance or Application award recognized the efforts of a company working in the expanding and promising field of personalized medicine. The judges said this exemplified a successful public-private collaboration that established the first qualified biomarker for a clinical indication under the FDA’s Drug Development Tool program.

April 27, 2016

WASHINGTON, D.C. - April 26, 2016 - The COPD Foundation today announced it has been approved for a $2.5 million funding award by the Patient-Centered Outcomes Research Institute (PCORI) for the O2VERLAP study, which will demonstrate the capabilities of the COPD Patient-Powered Research Network (COPD PPRN). The COPD PPRN is the largest research registry ever assembled in an effort to find improved therapies, and ultimately a cure, for COPD.

O2VERLAP is a multi-stakeholder project that will compare the effectiveness of patient-centered proactive care methods (web-based peer coaching education and support intervention) versus reactive care, on adherence to positive airway pressure and oxygen therapies in patients diagnosed with chronic obstructive pulmonary disease (COPD) and/or obstructive sleep apnea (OSA). As many as 4.5 million people in the U.S. have both COPD and OSA. Results from the O2VERLAP study will provide evidence to shape how care is delivered in the home for patients with COPD and OSA, and will provide guidance on the use of social media, peer-to-peer support, smartphone apps, and viral messaging to engage patients. The study will also serve as a recruitment tool for the COPD Patient-Powered Research Network, a subset of the National Patient-Centered Clinical Research Network (PCORnet), which prioritizes patient-guided research and personalized care.

The O2VERLAP project will also include the engagement of patient partners and stakeholders in a series of focus groups and interviews to understand treatment barriers and important outcomes to refine the development of a peer-led Internet-based coaching program for individuals with COPD and OSA. The COPD Foundation and partners at American Sleep Apnea Association and other members of PCORnet will engage in collaborative activities around O2VERLAP designed to create more efficient research methods, new tools and best practices for patient centered research.

April 22, 2016

WASHINGTON, D.C. - April 22, 2016 -The COPD Foundation is pleased to announce that it has been selected as a finalist for the Clinical & Research Excellence (CARE) awards in the Best Personalized Medicine Advance or Application category for its work on plasma fibrinogen.

The Chronic Obstructive Pulmonary Disease (COPD) Biomarker Qualification Consortium (CBQC) is a unique public-private partnership among the COPD Foundation, the pharmaceutical industry, academic experts, and the Food and Drug Administration. The intent of the CBQC is to facilitate the qualification of biomarkers that can be used for enrichment of clinical trial populations and/or as outcome assessments. Recently, the FDA approved the qualification of plasma fibrinogen as a prognostic or enrichment biomarker for all-cause mortality and COPD exacerbations. Plasma fibrinogen is the first biomarker drug development tool qualified for use in COPD under the FDA’s Drug Development Tool (DDT) qualification program.

February 25, 2016

WASHINGTON, D.C. - February 25, 2015 - Today at the Precision Medicine Initiative Summit at the White House, Joe Selby, MD, MPH, Executive Director of the Patient-Centered Outcomes Research Institute (PCORI), announced an initiative to enable individuals to access data in their electronic health records (EHRs) to share for research that could improve care for their conditions.

The initiative involves a pledge by 20 Patient-Powered Research Networks (PPRNs) to help their participating patients more readily obtain information from their electronic health records (EHRs). The COPD Patient-Powered Research Network (COPD PPRN) is a collaborative effort between the COPD Foundation and two federally-funded networks: COPD Outcomes-based Network for Clinical Effectiveness and Research Translation (CONCERT) and COPDGene.

The PPRNs will encourage their participant members to share their health information with researchers to support studies that have been identified as highly relevant and useful by network members. The PPRNs are uniquely positioned to facilitate the flow of health data for research and healthcare improvement because they are built to focus specifically on the needs of their participants.

February 25, 2016

WASHINGTON, D.C. - February 25, 2016 - The COPD Foundation congratulates Robert Califf, MD, on his confirmation as the new commissioner of the U.S. Food and Drug Administration (FDA).

The U.S. Senate confirmed Califf on February 24 by an overwhelming vote of 89-4. Califf, 63, joined the FDA as deputy commissioner in March 2015 after more than 30 years as a prominent cardiologist and medical researcher at Duke University. He is among the most cited medical authors in academia, with more than 1,200 journal articles.

“On behalf of the COPD Foundation, I am pleased that Commissioner Califf has been appointed to this new role. We look forward to working with him on many initiatives,” said Craig Kephart, Executive Director of the COPD Foundation. He continued, “I know our founder John W. Walsh thought incredibly highly of him and considered the Commissioner to be a leader in the healthcare field dedicated to advancing medicine.”

February 11, 2016

WASHINGTON, D.C. - February 11, 2016 - John Walsh, President and Co-Founder of the COPD Foundation is currently recovering from injuries incurred when he fell on the icy streets of Washington DC. In order to provide John with time to recover from his injuries and to assure the seamless continued operation of the COPD Foundation, the following appointment has been made. Craig Kephart, Executive Director of the COPD Foundation, has been appointed Acting President, reporting directly to the Chairman of the COPD Foundation Board, Dr. Byron Thomashow.

Our thoughts and well wishes go out to John during his recovery period and we remain committed to carrying on the vision he wholeheartedly embraced.

January 25, 2016

WASHINGTON, D.C. - January 25, 2016 - The U.S. Centers for Disease Control and Prevention (CDC) today launched its fifth year of ads featuring real people who are living with the effects of smoking-related diseases. The newest ads in the Tips from Former Smokers campaign tell the story of how real people’s lives were changed forever due to their smoking. These ads will run for 20 weeks on television, radio, billboards, online, and in magazines and newspapers.

Over 30 people have offered their voice and story to the Tips campaign since 2012. Each real story represents thousands and thousands of Americans affected by similar illnesses caused by smoking. Ads also highlight the benefits of quitting for loved ones, and the importance of quitting cigarettes completely, not just cutting down. They encourage smokers to call 1-800-QUIT NOW, a toll-free number to access free quitting support across the country, or to visit www.cdc.gov/tips to view the personal stories from the campaign and for free help quitting.

For more information on the campaign, including profiles of the former smokers, links to the ads, and free quit help, visit www.cdc.gov/tips.

January 12, 2016

WASHINGTON, D.C. - January 12, 2016 -The COPD Foundation (COPDF) would like to congratulate Dr. Robert Califf on the unanimous approval of his nomination for FDA commissioner by the Senate HELP Committee. COPDF thanks Chariman Alexander, Ranking Member Murray, and the committee for moving the nomination process to the full Senate, and encourages the immediate confirmation of Dr. Califf for the position.

A seasoned leader, the COPD Foundation believes Dr. Califf will effectively serve patient communities across the country while improving the FDA’s drug approval process. His extensive experience will serve as a significant resource in strengthening the stakeholder and patient relationship. The Foundation has joined 50 healthcare organizations urging his immediate confirmation by the Senate.

December 18, 2015

WASHINGTON, D.C. - December 18, 2015 - The COPD Foundation today announced they have been awarded the 2015 Aesculapius Award for excellence in health communication by Dr. Peter G. Goldschmidt, president and founder of the Health Improvement Institute. The Aesculapius Award of Excellence is given to organizations that excel in providing health information to the public via web communications. Each year, a panel of judges who represent healthcare, web publishing, and multimedia fields evaluate entries and select one website and one public service announcement to receive the top prize. Recipient of the 2015 Award of Excellence for health-related websites was the COPD Foundation for their entry of www.COPD360social.org.

“COPD360social was developed to serve our community as a one-stop-shop for all things related to COPD,” said John W. Walsh, president and co-founder of the COPD Foundation. “We have seen tremendous growth since our launch in November 2014, with 10,000 new members connecting and providing one another with guidance and support. The site not only provides our members with unique access to experts and free educational material, but a respite from the social isolation that is pervasive in the COPD population. We are pleased to receive this distinction from the Health Improvement Institute and will continue to leverage online communications tools to serve the COPD community.”

December 11, 2015

ALISO VIEJO, CA - December 10, 2015 - Predixion Software, a developer of cloud-based advanced analytics software, today announced that the COPD Foundation, the only U.S. healthcare nonprofit dedicated to preventing and curing chronic obstructive pulmonary disease (COPD), has selected Predixion and Carolinas HealthCare System to deliver the world’s first program to predict and prevent hospital readmissions for COPD patients with co-morbidities. A respiratory disease affecting approximately 30 million people in the U.S., COPD is the third leading cause of death in the country with one of the highest rates of unplanned hospital readmissions.

Page 1 of 22First   Previous   [1]  2  3  4  5  6  7  8  9  10  Next   Last   

Join Us on COPD360social

Sign In to Participate
Or register to become a member
Minimize

Search Press Releases

3.8. million due to complications